[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"crps-complex-regional-pain-syndromes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:crps-complex-regional-pain-syndromes":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100629358","perineural-incobotulinumtoxin-a-for-complex-regional-pain-syndrome---an-open-label-feasibility-study-100629358",false,"NCT07473635","Perineural Incobotulinumtoxin-A for Complex Regional Pain Syndrome - An Open-label Feasibility Study","Perineural Incobotulinumtoxin-A for Complex Regional Pain Syndrome - An Open-label Feasibility Study (PINCom)","PINCom","Inclusion Criteria:\n\n* Are over the age of 18\n* Have a diagnosis of CRPS type 1 or 2 in either one upper or one lower extremity which fulfils the Budapest research criteria\n* Have had the condition for at least 6 months\n* Rate CRPS as their primary pain condition\n* Have been on a stable analgesic regimen, including any rescue medications, for at least 1 month prior to the study and intend to maintain this regimen throughout the study\n* For pre-menopausal females: are using a safe and approved contraceptive\n* Speak, read, and understand Danish\n\nExclusion Criteria:\n\n* Are allergic to botulinum toxin A\n* Have been treated with botulinum toxin A for any indication within 3 months prior to study start\n* Are diagnosed with myasthenia, Lambert-Eaton syndrome, amyotrophic lateral sclerosis, or any other condition which makes differentiation of CRPS-specific pain difficult\n* Have an ongoing infection in the affected limb\n* Do not intend to start physical therapy, psychotherapy, or any other non-pharmaceutical intervention aimed at reducing pain\n* Have used a topical analgesic treatment such as lidocaine patches within 1 week prior to study start or have been treated with capsaicin patches in the affected area within 3 months prior to study start\n* Have psychiatric comorbidities which are considered by the investigators to impact their ability to participate\n* Consume alcohol in excess of what is recommended by the Danish Health Ministry\n* Are active abusers of illicit narcotics\n* Are pregnant, lactating, or plan on becoming pregnant during the study period\n* Have any other condition or circumstance that, in the investigators' opinion, will hinder safe and timely participation and completion of the study","ALL","18 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"NA","Complex Regional Pain Syndrome (CRPS) is a chronic pain condition characterized by severe regional pain, sensory disturbances, and functional impairment. Current treatment options are limited, and many patients experience substantial pain-related disability and symptom fluctuations, including flare-ups triggered by invasive procedures.\n\nPerineural administration of botulinum toxin A has shown analgesic effects in other neuropathic pain conditions and may represent a less painful alternative to subcutaneous injection techniques. However, the feasibility, tolerability, and safety of perineural botulinum toxin administration in patients with CRPS have not been systematically evaluated.\n\nThe PINCom study is a single-center, open-label feasibility study designed to assess the safety, tolerability, and practical feasibility of ultrasound-guided perineural injection of incobotulinumtoxin-A in patients with unilateral chronic CRPS affecting an upper or lower limb. Participants receive a single perineural injection targeting major sensory nerves supplying the affected limb and are followed for 12 weeks.\n\nPrimary outcomes focus on feasibility metrics, including recruitment, retention, adherence, and data completeness, as well as safety outcomes, including serious adverse events and procedure-related complications. Tolerability is assessed through monitoring of CRPS flare-ups and a dedicated qualitative interview exploring participant experience. Exploratory outcomes include pain intensity, CRPS severity, and patient-reported measures collected to inform the design of a future randomized controlled trial.",[27,28,29],"CRPS (Complex Regional Pain Syndromes)","CRPS (Complex Regional Pain Syndrome) Type I","CRPS Type II",[31,32,33,34],"botulinum toxin","CRPS","Pilot","perineural","RECRUITING","2026-03-10",{"date":38,"type":39},"2026-03-16","ACTUAL",{"date":41,"type":39},"2026-01-07",{"date":43,"type":21},"2026-08-01",{"name":45,"class":46},"Bo Biering-Soerensen","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":47},"100432286","intermittent-dosing-of-dorsal-root-ganglion-stimulation-as-an-alternate-paradigm-to-continuous-low-frequency-therapy-100432286","NCT04909138","Intermittent Dosing of Dorsal Root Ganglion Stimulation as an Alternate Paradigm to Continuous Low-Frequency Therapy","Inclusion Criteria:\n\n* Age between 18 and 99\n* 1-year or more use of continuous DRG therapy as delivered a permanently implanted Abbott PROCLAIM XR Dorsal Root Ganglion Neurostimulator System for chronic back and\u002For leg pain\n* Endorse at least 50% pain relief in the targeted area over the last year\n* Must have been seen for routine follow-up within last 4 months\n* Must have been reprogrammed in standard fashion at least once prior to randomization\n* Willing and able to complete protocol requirements, including:\n\n  * Complete health questionnaires and pain scales as specified in the protocol\n  * Sign the study-specific informed consent form\n  * Complete follow-ups at the designated time periods\n\nExclusion Criteria:\n\n* Significant lead migration, as determined by clinician\n* Other concurrent neuromodulation system in place\n* Corticosteroid injection in previous 30 days prior to enrollment\n* Intermittent dosing and\u002For failure within last 6m\n* Changing or unstable pain medications within 30 days","90 Years",{"count":56,"type":21},30,[24],"This study seeks to evaluate the use of intermittent dosing as an alternative paradigm for patients with DRG stimulation in place for at least 1 year and minimum 50% pain relief in the targeted area.\n\nPatients will be prospectively randomized to one of two stimulation paradigms both of which involve intermittent dosing at 30 seconds ON and 90 seconds OFF. Group 1 will have their frequency set at 20 Hz with amplitude levels adjusted in order to remain in the therapeutic window (subthreshold stimulation). Group 2 will have their frequency set at 5 Hz with amplitude levels adjusted in order to remain in the therapeutic window (subthreshold stimulation) This study will be performed in a crossover fashion, meaning patients will be changed to the alternate dosing regimen at the 13-week time period.\n\nPatients will be seen and evaluated prior to randomization and reprogramming, and thereafter evaluated at 4, 8, and 12-weeks. At the 12-week time period, patients will begin a 1-week washout period of continuous stimulation. At the 13-week time period, patients will be evaluated, crossed over to the other study arm and thereafter evaluated at 17, 21, and 25-weeks.",[27,60,61],"Radiculopathy","Peripheral Neuropathy",[63,64],"Chronic Pain","Dorsal Root Ganglion Stimulation","2026-01-18",{"date":67,"type":39},"2026-01-21",{"date":69,"type":39},"2022-10-15",{"date":71,"type":21},"2027-06",{"name":73,"class":46},"Rush University Medical Center",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":87,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":47},"100608997","the-effectiveness-of-conservative-treatment-in-patients-with-complex-regional-pain-syndrome-100608997","NCT07208825","The Effectiveness of Conservative Treatment in Patients With Complex Regional Pain Syndrome.","The Effectiveness of Individualized Physical Therapy and Functional Neurology Treatment Protocol in Conjunction With Optimizing Medication and Repetitive Transcranical Magnetic Stimulation in Patients With Complex Regional Pain Syndrome.","Inclusion Criteria:\n\n* CRPS symptoms maximum of 5 year at the time of diagnosis (CRPS 1 and 2)\n* 18 to 70-year-old\n* rTMS treatment is granted by university hospital pain clinic (by multidisciplinary group)\n* Voluntary to participate into the study\n\nExclusion Criteria:\n\n* CRPS symptoms started over five years ago (although diagnosed first time now)\n* No other outpatient\u002Finpatient rehabilitation during the study rehabilitation period (insurance company or other third party)\n* Under 18-years-old of over 70-years-old\n* No eligible to rTMS treatment or for other reason rTMS treatment was not granted by university hospital pain clinic (by multidisciplinary group)","70 Years",{"count":83,"type":21},156,[24],"The aim of the study is to investigate and improve non-pharmacological rehabilitation methods for patients with Complex Regional Pain Syndrome (CRPS) to reduce pain and restore work and functional capacity to lower overall treatment costs. Current treatment methods offer limited rehabilitation potential for this challenging pain condition, so efforts should be made to raise the level of care and rehabilitation for a disease that often causes long-term and severe reductions in patients' functional and occupational abilities. CRPS patients almost always have to substantially reduce their work hours or withdrawn from the workforce for extended periods, and often permanently, increasing the urgency of strengthening rehabilitation approaches; a CRPS symptoms can end a patient's productivity for society. In addition, commonly used medications are a significant expense for both individuals and the healthcare system. CRPS rarely resolves fully, and even with extensive rehabilitation only a small proportion of patients regain sufficient improvement to return to work at a level of at least 60% capacity.\n\nParticipants will be recruited from the Department of Physical Medicine and Rehabilitation at Oulu University Hospital, where CRPS diagnostics for the Northern Ostrobothnia area are primarily conducted. The study will be carried out at OYS rehabilitation outpatient clinics. A total of 39 participants will be recruited into each of four study groups, for an overall sample size of 156 individuals. Each study group will receive repetitive transcranial magnetic stimulation (rTMS) at some point, and functional neurological rehabilitation will be combined with rTMS in varying ways (content and timing will differ between groups). All participants will receive basic CRPS rehabilitation (physiotherapy and occupational therapy) that is provided for all RPS patients, and the timing of this relative to rTMS will also be varied. Recruitment is planned to begin in a autumn 2025.",[27],[32,88,89,90,91,92,93],"GMI","Graded motor imaginary","Rehabilitation","Functional neurology","rTMS","medication","2025-09-28",{"date":96,"type":39},"2025-10-06",{"date":98,"type":21},"2025-09-30",{"date":100,"type":21},"2033-12-31",{"name":102,"class":46},"Oulu University Hospital"]